IJSTR

International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
0.2
2019CiteScore
 
10th percentile
Powered by  Scopus
Scopus coverage:
Nov 2018 to May 2020

CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT

IJSTR >> Volume 8 - Issue 8, August 2019 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Insilico Analysis Of Docking Studies CGSP Strain Of Streptococcus Pneumoniae

[Full Text]

 

AUTHOR(S)

Balasankar Karavadi, Sai Aakarsha S, Rajasekar. B, Premalatha. J

 

KEYWORDS

Streptococcus pneumonia, CGSP14, Target, Protein, Ligand.

 

ABSTRACT

Various current examinations are done on the effectiveness of characteristic parts to battle the intrusion by Streptococcus pneumoniae strain CGSP14. The primary goal is to propose the most good simple exacerbate that could be viable to focus on the protein. This consideration has been picked up as before cases as a rule established in medication improvement. These cases and contextual investigations give interfaces between target proteins and the analogs. Numerous other comparative works have been found to discover most ideal ligand intensify that could be successful to focus on the target protein.

 

REFERENCES

[1]. Argondizzo AP, da Mota FF, Pestana CP, Reis JN, de Miranda AB, Galler R, Medeiros MA.,Identification of proteins in Streptococcus pneumoniae by reverse vaccinology and genetic diversity of these proteins in clinical isolates, 175(4):2124-65, 2015 Feb.
[2]. Blue, C. E., and T. J. Mitchell. Contribution of a response regulator to the virulence of Streptococcus pneumoniae is strain dependent. Infect. Immun. 71:4405-4413. 2003.
[3]. Bender MH, Cartee RT, Yother J, Positive correlation between tyrosine phosphorylation of CpsD and capsularpolysaccharide production in Streptococcus pneumonia, J. Bacteriol, 185, 6057, 2003.
[4]. Brueggemann AB, Pai R, Crook DW, Beall B, Vaccine escape recombinants Emerge after pneumococcal vaccinationin the United States, PLoS. Pathog, 3, 168, 2007. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001; 293:498-506.
[5]. Cardoso TC, Lopes LM, Carneiro AH. A case-control study on risk factors for early-onset respiratory tract infection in patients admitted in ICU. BMC Pulm. Med. 2007; 7:12-17.
[6]. Del Toro MD, Rodriguez-Bano J, Martinez-Matinez L, Pasculal A, Perez-Canoa R, Perea EJ et.al. Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas lmaltophilia. Enferm. Infecc. Microbiol. Clin. 2006; 24:4-9.
[7]. Orihuela CJ, Gao G, McGee M, Yu J, Francis KP, Tuomanen EI. Tissue-specific contribution of pneumococcal virulence factors to pathogenesis. J. Infect. Dis. 2004; 190:1661-1669.
[8]. Orihuela CJ, Gao G, McGee M, Yu J, Francis KP, Tuomanes EI. Organ-specific models of Streptococcus pneumoniae disease. Scand. J.Infect. 2003; 35:647-652.
[9]. Karavadi B, Suresh MX. Homology modelling and molecular drug design approach in identifying drug targets of TIGR4 in Streptococcus pneumonia
[10]. BiosciBiotechnol Res Asia; 11: 517-22, 2014.
[11]. Karavadi B, Suresh MX. In silicomodeling of capsular polysaccharidebiosynthesis protein and tyrosine kinase of G54 strain in Streptococcuspneumoniae and their ligand identification. Int J Pharm PharmSci; 6:547-50, 2014.
[12]. Karavadi B, Suresh XM. Homology modeling of polymerase and CPSbiosynthesis proteins in CGSP14 strain of Streptococcus pneumoniaand its ligand identification: An in silico approach. Asian J Pharm Clin Res; 7:162-5, 2014.
[13]. Lanie JA, et al. J Bacteriol, Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. 189(1), 38–51, 2007 Jan
[14]. McCullers JA, Tuomanen EI, Molecular pathogenesis of pneumococcal pneumonia. Front Biosci, 6, 877-889, 2001.
[15]. Orihuela. CJ, Gao. M, McGee, J.Yu, Francis.KP, and Tuomanes.E, Organ-specific models of Streptococcus pneumoniae disease. Scand. J.Infect, 35, 647-652, 2003
[16]. Plotkin SA, Orenstein W, Offit PA. Vaccines. Philadelphia, PA: Elsevier– Saunders, p. 542-51, 2012.
[17]. Shak. JR, Ludewick. HP, Howery. KE, Sakai. F, Yi. H, Harvey. RM et.al., Novel Role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of Biofilms. MBio, 4(5), 655-13., 2013.